On behalf of UCB Pharma Ltd, we would like to invite you to attend the webinar From Skin to Joints: UCB promotional webinar on Monday 16th October from 18:30 – 19:15.
This promotional webinar is part of the ongoing Dermatology Nurse Academy series and is organised and sponsored by UCB Pharma Ltd. This is open to Dermatology Specialist Nurses.
Speaker: Dr Georgina Fremlin, Consultant Dermatologist, University Hospitals Birmingham NHS Foundation Trust.
This promotional webinar is for GB, NI and ROI healthcare professionals only. UCB Pharma Ltd products will be discussed.
BIMZELX® ▼ (bimekizumab) is indicated for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Alone or in combination with methotrexate, for active psoriatic arthritis in adults who have had an inadequate response or intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk for GB and NI and www.hpra.ie/homepage/about-us/report-an-issue for ROI. Adverse events should also be reported to UCB Pharma Ltd. Email: UCBCares.UK@UCB.com or 0800 2793177 and UCBCares.IE@ucb.com
IE-P-BK-PSO-2300072 | October 2023